Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.42% | -6.81% | -28.99% | -50.42% | -43.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 120.33% | -49.36% | -68.78% | -65.12% | 3.62% |
| Operating Income | -120.33% | 49.36% | 68.78% | 65.12% | -3.62% |
| Income Before Tax | -98.20% | 46.61% | 44.89% | 57.18% | 0.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -98.20% | 46.61% | 44.89% | 57.18% | 0.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.20% | 46.61% | 44.89% | 57.18% | 0.29% |
| EBIT | -120.33% | 49.36% | 68.78% | 65.12% | -3.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -76.74% | 52.08% | 45.69% | 57.14% | 0.00% |
| Normalized Basic EPS | -77.78% | 53.33% | 45.53% | 56.63% | 0.00% |
| EPS Diluted | -76.74% | 52.08% | 45.69% | 57.14% | 0.00% |
| Normalized Diluted EPS | -77.78% | 53.33% | 45.53% | 56.63% | 0.00% |
| Average Basic Shares Outstanding | 12.58% | 12.57% | 1.78% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 12.58% | 12.57% | 1.78% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |